Clinical trial Recruiting at 1 site Observational Ages 12 and up

Evolution of Chronic Inflammatory Skin Diseases in Everyday Practice

Official title: Evolution of Chronic Inflammatory Skin Diseases

Run by Fondazione Policlinico Universitario Agostino Gemelli IRCCS · NCT07708896 · Data updated 2026-11-12

This study follows people aged 12 and older with common inflammatory skin conditions to see how their disease changes over time using routinely collected clinical data.

Quick facts

Study typeObservational
Ages12 Years and up
SexAll
Enrollment5000 (estimated)
SponsorFondazione Policlinico Universitario Agostino Gemelli IRCCS
Academic / other
Locations1 site (Rome)
StatusRecruiting
StartedJuly 1, 2026
Main results expectedJuly 2030
Study endsJuly 2036
Registry record updatedSeptember 25, 2026
Trial IDNCT07708896 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are patients aged 12 years or older with a confirmed diagnosis of AD, PN, PSO, CHE, or HS who have baseline data and regular follow-up visits at the Gemelli IRCCS dermatology clinic.

Probably not a fit

Patients without sufficient longitudinal data or who do not receive follow-up visits may not benefit from the study insights.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a monocentric observational study that combines retrospective and prospective data to describe how chronic inflammatory skin diseases progress. It collects demographic, clinical, therapeutic, and clinimetric information from patients with atopic dermatitis, psoriasis, prurigo nodularis, chronic hand eczema, and hidradenitis suppurativa. The study analyzes changes in disease severity over a 7-year retrospective window and a 10-year prospective follow-up, aiming to identify factors that predict moderate-to-severe disease and unfavorable outcomes. Interventions focus on advanced systemic therapies as part of routine clinical care. Eligible participants are patients aged 12 years or older attending dermatology clinics who have sufficient data at baseline and during follow-up.

Why it matters

Potential benefit: If successful, the study could improve understanding of how these diseases evolve and help identify factors associated with worse outcomes to guide future care.

How similar studies have gone: Similar observational studies have provided useful descriptions of disease trajectories in chronic inflammatory skin diseases, though this specific combination and design is relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Age ≥12 years.
* Patients with a confirmed clinical diagnosis of atopic dermatitis (AD), prurigo nodularis (PN), psoriasis (PSO), chronic hand eczema (CHE), or hidradenitis suppurativa (HS) attending the dermatology outpatient clinics of Fondazione Policlinico Universitario A. Gemelli IRCCS.
* Availability of clinical data at baseline and at subsequent follow-up visits performed according to routine clinical practice.

Exclusion Criteria:

* Age \<12 years; absence of the minimum required data (treatment start date and at least one follow-up visit with a clinical score).
* Refusal or inability to understand and sign the informed consent form.

Where it's running

  • Fondazione Policlinico Agostino Gemelli IRCCS
    Rome, Italy
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.